August 26, 2015 8:00 AM
Parkinson’s Disease is the second most
common neurodegenerative disorder, after Alzheimer’s disease, affecting about
seven to ten million people around the world. It is characterized by
progressive neurological impairment that produces tremor, slowness of movement,
impaired balance, muscle rigidity, cognitive decline and other medical
disturbances. The symptoms are caused by the death of cells in the nervous
system, including those that generate dopamine, which is a chemical
neurotransmitter that sends signals between nerve cells. Although specific gene
mutations have been identified in a minority of patients, there is no known
cause in most individuals. There is currently no cure for Parkinson’s Disease.
A team led by Dr. Matthew Hebb, a
neurosurgeon-researcher at Lawson and Western University’s Department of
Clinical Neurological Sciences has been developing innovative strategies to study
Parkinson’s Disease. “The partnership with STEMCELL Technologies greatly
expands the expertise focused on moving this technology forward and providing
critical access to researchers worldwide.” says Dr. Hebb.
Commenting on the agreement:
“We are delighted for the opportunity to
bring these important products to the research community and we are excited to
be the exclusive supplier.”
- Dr. Allen Eaves, CEO and President of
STEMCELL Technologies
“Lawson’s partnership with STEMCELL
Technologies is critically important to provide global access to these novel
research tools that are anticipated to enable unique insights into the disease
process.”
- Kirk Brown, Manager, Business
Development, Lawson
“Lawson is very pleased to partner with
STEMCELL Technologies to make these products available to all researchers, with
the immediate goal of moving Parkinson’s Disease research forward and the
ultimate goal that it will lead to better treatment options for patients.”
- Dr. David Hill, Scientific Director,
Lawson
About Lawson
As the research institute of London
Health Sciences Centre and St. Joseph's Health Care London, and working in
partnership with Western University, Lawson Health
Research Institute is committed to furthering scientific knowledge
to advance health care around the world. Commercialization at Lawson is facilitated
by WORLDiscoveries®,
a joint venture of Lawson, Western, and Robart’s Research Institute. As the
business development arm of London, Ontario’s extensive research network, it is
a bridge between local invention and global industry.
About STEMCELL Technologies
As Scientists Helping Scientists,
STEMCELL Technologies Inc. is committed to providing high-quality cell culture
media, cell isolation products and accessory reagents for life science
research. Driven by science and a passion for quality, STEMCELL Technologies
provides over 2000 products to more than 70 countries worldwide. STEMCELL
Technologies’ specialty cell culture reagents, instruments and tools are
designed to support science along the basic to translational research
continuum. To learn more, visit www.stemcell.com.
Contact:
For more information, please contact:
Lawson - Laura Goncalves
Communications & External Relations
T: 519-685-8500 ext. 64059
C: 226-448-1525
laura.goncalves@lawsonresearch.com
https://twitter.com/lawsonresearch
STEMCELL – LubaMetlitskaia, MSc.
Director, Licensing and Business Development
e-mail: bdv@stemcell.com
visit us at: www.stemcell.com
No comments:
Post a Comment